Surgical Trauma, Minimal Residual Disease and Locoregional Cancer Recurrence

Ceelen, Wim; Morris, Sophie; Paraskeva, Paraskevas; Pattyn, Piet

doi:10.1007/978-0-387-48993-3_4

Cited by 14 publications

(18 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We did not find prospective randomized clinical trials providing Level 1 evidence in favor or against such side-effect of management so that the present discussion is admittedly speculative. 4,115 Surgical interventions make wounds and will inevitably elucidate myofibroblast stimulation as part of the healing process. This makes a better niche for growth and invasion of cancer cells that were eventually spillled in the operation field.…”

Section: Characterization and Origin Of A Myofibroblastmentioning

confidence: 99%

“…To counteract this potential drawback, they are considering minimal surgical trauma and postoperative anti-inflammatory treatment. 115,118 Comparison between conventional and laparoscopic-assisted surgery for colorectal cancer illustrates the multiple variables that are implicated in such analysis and that make conclusions difficult. 115,119 Apart from differences in the extent of the surgical trauma, the effect of the carbon dioxide pneumoperitoneum, applied for laparoscopy, upon the metabolism of the cancer cells including invasive and metastatic stimuli should be taken into consideration.…”

Section: Characterization and Origin Of A Myofibroblastmentioning

confidence: 99%

See 1 more Smart Citation

Stromal myofibroblasts are drivers of invasive cancer growth

Wever¹,

Demetter²,

Mareel³

et al. 2008

Intl Journal of Cancer

625

601

View full text Add to dashboard Cite

Tissue integrity is maintained by the stroma in physiology. In cancer, however, tissue invasion is driven by the stroma. Myofibroblasts and cancer-associated fibroblasts are important components of the tumor stroma. The origin of myofibroblasts remains controversial, although fibroblasts and bone marrow-derived precursors are considered to be the main progenitor cells. Myofibroblast reactions also occur in fibrosis. Therefore, we wonder whether nontumorous myofibroblasts have different characteristics and different origins as compared to tumor-associated myofibroblasts. The mutual interaction between cancer cells and myofibroblasts is dependent on multiple invasive growth-promoting factors, through direct cell-cell contacts and paracrine signals. Since fibrosis is a major side effect of radiotherapy, we address the question how the main methods of cancer management, including chemotherapy, hormonotherapy and surgery affect myofibroblasts and by inference the surrogate endpoints invasion and metastasis.

show abstract

Section: Characterization and Origin Of A Myofibroblastmentioning

confidence: 99%

Section: Characterization and Origin Of A Myofibroblastmentioning

confidence: 99%

Stromal myofibroblasts are drivers of invasive cancer growth

Wever¹,

Demetter²,

Mareel³

et al. 2008

Intl Journal of Cancer

625

601

View full text Add to dashboard Cite

show abstract

“…Another unavoidable consequence of surgical trauma is induction of metastatic potential in the microscopic tumors that are not eliminated through tumor resection (Ceelen et al, 2007, 2014). Numerous mitogenic and pro-angiogenic factors, such as transforming growth factor beta (TGF-β), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF)-like growth factors, endostatin etc., were found in the wound fluids which explains the stimulation of cancer cell proliferation and neoangiogenesis during post-surgery wound healing period (Maniwa et al, 1998; Abramovitch et al, 1999; Wu et al, 2003).…”

Section: Pharmacological Properties Of Tq Indicates Its Potential Rolmentioning

confidence: 99%

Thymoquinone as a Potential Adjuvant Therapy for Cancer Treatment: Evidence from Preclinical Studies

et al. 2017

View full text Add to dashboard Cite

Thymoquinone (TQ), the main bioactive component of Nigella sativa, has been found to exhibit anticancer effects in numerous preclinical studies. Due to its multitargeting nature, TQ interferes in a wide range of tumorigenic processes and counteracts carcinogenesis, malignant growth, invasion, migration, and angiogenesis. Moreover, TQ can specifically sensitize tumor cells toward conventional cancer treatments (e.g., radiotherapy, chemotherapy, and immunotherapy) and simultaneously minimize therapy-associated toxic effects in normal cells. In this review, we summarized the adjuvant potential of TQ as observed in various in vitro and in vivo animal models and discussed the pharmacological properties of TQ to rationalize its supplementary role in potentiating the efficacy of standard therapeutic modalities namely surgery, radiotherapy, chemotherapy, and immunotherapy. Altogether, we suggest further comprehensive evaluation of TQ in preclinical and clinical levels to delineate its implied utility as a novel complementary adjuvant therapy for cancer treatment.

show abstract

“…Furthermore, the inflammatory process associated with surgery shares mediators with tumor growth and invasion. Macrophages, fibroblasts and humoral factors of inflammation have been shown to enhance tumor growth in preclinical models [19, 20]. …”

Section: The Perioperative “Window Of Opportunity”mentioning

confidence: 99%

Metastasis: Recent Discoveries and Novel Perioperative Treatment Strategies with Particular Interest in the Hemostatic Compound Desmopressin

Alonso

Ripoll

Garona³

et al. 2011

CPB

View full text Add to dashboard Cite

Metastatic disease is responsible for most of cancer lethality. A main obstacle for therapy of advanced cancers is that the outcome of metastasis depends on a complex interplay between malignant and host cells. The perioperative period represents an underutilized window of opportunity for cancer treatment where tumor-host interactions can be modulated, reducing the risk of local recurrences and distant metastases. Blood-saving agents are attractive compounds to be administered during tumor surgery. Desmopressin (DDAVP) is a safe and convenient hemostatic peptide with proved antimetastastic properties in experimental models and veterinary clinical trials. The compound seems to induce a dual angiostatic and antimetastatic effect, breaking the cooperative function of cancer cells and endothelial cells during residual tumor progression. DDAVP is therefore an interesting lead compound to develop novel synthetic peptide analogs with enhanced antitumor properties.

show abstract

Surgical Trauma, Minimal Residual Disease and Locoregional Cancer Recurrence

Cited by 14 publications

References 103 publications

Stromal myofibroblasts are drivers of invasive cancer growth

Stromal myofibroblasts are drivers of invasive cancer growth

Thymoquinone as a Potential Adjuvant Therapy for Cancer Treatment: Evidence from Preclinical Studies

Metastasis: Recent Discoveries and Novel Perioperative Treatment Strategies with Particular Interest in the Hemostatic Compound Desmopressin

Contact Info

Product

Resources

About